Downloaded from https://www.everyspec.com e. See the DCS, G–1 Personnel Policy Guidance Message for additional deployment requirements on the DCS, G–1 web site at http://www.armyg1.army.mil/militarypersonnel/mission.asp. Medical standards for deployment are meant as general guides. The final recommendation is based on clinical judgment and commander input, which considers the geographical area in which the Soldier will be assigned and the potential environmental/austere conditions to which the Soldier may be subject.
The following medical conditions must be reviewed carefully by the clinician before making a recommendation as to whether the Soldier can deploy to duty in a combat zone (or austere isolated area where medical treatment may not be readily available). (1) Diabetes requiring insulin. This requires an MEB/PEB (or for the RC, processing under paras 9–10 and 10–26). If found fit for duty, the Soldier should not deploy to areas where insulin cannot be properly stored (stored above freezing level but at less than 86 degrees Fahrenheit) or appropriate medical support cannot be reasonably assured. Deployment should only follow predeployment review and recommendation by an endocrinologist.
(2) Diabetes requiring oral medication for control. This requires a MEB/PEB (or for the RC processing under paras 9–10 and 10–26). If found fit for duty by a PEB, the Soldier may or may not be worldwide deployable (see table 5–1 for medical qualifications). (3) Cardiovascular conditions.. Review paragraphs 3-21 through 3-24 to determine if an MEB/PEB/trial of duty (or processing under paras 9-10 and 10-26 ) is necessary. If the Soldier successfully completes a trial of duty and is found fit for duty (or returned to duty by a Medical MOS Retention Board (MMRB)), the Soldier should not be deployed with any of the following conditions— (a) Hypertension not controlled with medication.
(b) Recent episodes necessitating emergency room visits or closely monitored follow-up care. (c) Permanent pacemakers, implanted antitachycardia and automatic implantable cardiac defibrillator (AICD) de- v i c e s , a n d s i m i l a r n e w l y d e v e l o p e d i m p l a n t e d c a r d i a c d e v i c e s r e q u i r e r e g u l a r m o n i t o r i n g f o r b a t t e r y l i f e a n d functionality and should not be exposed to high electromagnetic fields. These particular devices have upper extremity physical limitations. (d) Conditions requiring anticoagulants. (e) Bare metal coronary stents.
If the Soldier is found fit for duty by a PEB, the Soldier must remain at a location with access to a medical facility with the capability to do an urgent/emergent cardiac catheterization and laboratory monitoring of anti-platelet therapy for 3 months from the date of stent placement. (f) Drug eluting coronary stents. If the Soldier is found fit for duty by a PEB, the Soldier must remain at a location with access to a medical facility with the capability to do an urgent/emergent cardiac catheterization and laboratory monitoring of anti-platelet therapy for 6 months from the date of stent placement. (g) Closure device for patent foramen ovale or atrial septal defect.
If the Soldier is found fit for duty by a PEB, the Soldier must remain at a location with access to a medical facility with echocardiography, cardiology and laboratory monitoring of anti-platelet therapy capabilities for 6 months from the date of the closure of the defect. (h) Cardiac arrhythmias. If the Soldier has undergone an electrophysiology ablation procedure and the Soldier is found fit for duty by a PEB, the Soldier must remain at a location with access to cardiac monitoring capabilities for 6 months from the date of the ablation procedure. (i) Smallpox vaccine associated myocarditis.
If after an evaluation by a cardiovascular specialist, the Soldier is found to meet medical retention standards, the Soldier must remain at a location with access to echocardiography and medical monitoring for 6 months from the date myocarditis was diagnosed. (4) Neurological conditions. Review paragraph 3–30 for profile guidance and MEB/PEB processing criteria. (a) Seizure disorders. If the Soldier is controlled with medications and seizure free for one year, the Soldier may be assigned overseas but should not be assigned to areas where access to medications or where the ability to monitor anticonvulsant drug levels are not available. (b) Demyelinating conditions.
If a Soldier has been found fit for duty by a PEB (see paragraph 3–30 e ) for stable non-disqualifying demyelinating disease, the Soldier should not be subjected to austere environments or where there is no readily available access to environments of equal to or less than 80 degrees Fahrenheit. (5) Asthma. See paragraph 3–27 a for profile guidance and for MEB/PEB processing criteria. If it is determined that the Soldier can be returned to duty, the Soldier should not deploy if he/she cannot wear protective gear, has experienced recent emergency room visits, or requires repetitive use of oral corticosteroids. (6) Sleep apnea.
See paragraph 3-41c for profile guidance and for MEB processing criteria. The Soldier can be deployed if nasal continuous positive airway pressure (CPAP) is required and can be supported in the area of deployment. Criteria for the ability to use nasal CPAP in the area of deployment include the following: availability of a reliable power source; absence of environmental factors that would render electrical equipment inoperable or unreli- able, and the availability of a reliable source of replacement supplies such as masks, harnesses, and filters.
A Soldier that requires nasal CPAP should not be deployed if these factors cannot be assured and the absence of nasal CPAP would hinder the Soldier from performing his/her military duties. (7) Musculoskeletal. Soldiers with any recent musculoskeletal injury or surgery that prevents necessary mobility or firing a weapon should not deploy. Any chronic condition that restricts performance in the Soldier’s MOS (for example, low back pain that prevents lifting) should be referred to an MEB/PEB (or processed under paras 9–10 and 59 AR 40–501 • 14 December 2007